Elsevier

Gene

Volume 569, Issue 1, 10 September 2015, Pages 1-6
Gene

Gene wiki review
Atrial natriuretic peptide in cardiovascular biology and disease (NPPA)

https://doi.org/10.1016/j.gene.2015.06.029Get rights and content

Highlights

  • Atrial natriuretic peptide (ANP) is a hormone that regulates salt-water balance.

  • ANP acts in the heart to prevent cardiac hypertrophy.

  • ANP also regulates vascular remodeling and energy metabolism.

  • ANP variants are associated with cardiovascular and metabolic diseases.

Abstract

Atrial natriuretic peptide (ANP) is a cardiac hormone that regulates salt-water balance and blood pressure by promoting renal sodium and water excretion and stimulating vasodilation. ANP also has an anti-hypertrophic function in the heart, which is independent of its systemic blood pressure-lowering effect. In mice, ANP deficiency causes salt-sensitive hypertension and cardiac hypertrophy. Recent studies have shown that ANP plays an important role in regulating vascular remodeling and energy metabolism. Variants in the human NPPA gene, encoding the ANP precursor, are associated with hypertension, stroke, coronary artery disease, heart failure (HF) and obesity. ANP and related peptides are used as biomarkers for heart disease. Recombinant proteins and small molecules that enhance the ANP pathway have been developed to treat patients with HF. In this review, we discuss the role of ANP in cardiovascular biology and disease.

Introduction

Maintaining salt-water balance is of fundamental importance for all animals. The discovery of the natriuretic activity in rat atrial extracts by de Bold et al. established a previously suspected cardiac endocrine function in regulating body fluid homeostasis (de Bold et al., 1981). The responsible molecule later was found to be atrial natriuretic factor (ANF), also called atrial natriuretic peptide (ANP) (de Bold, 1985). Under high blood volume and pressure, heart muscle cells release ANP into the circulation. In the kidney, ANP enhances salt and water excretion. In the blood vessel, ANP promotes vasodilation. As such, ANP acts as a cardiac hormone to regulate blood volume and pressure. Defects in the ANP pathway are now known to contribute to major diseases such as hypertension, cardiac hypertrophy and heart failure (HF). More recently, ANP and related peptides have been implicated in lipid metabolism and metabolic disease. In this review, we discuss the role of ANP in cardiovascular biology and disease.

Section snippets

The NPPA gene

In mammals, the natriuretic peptide family has three members: ANP, brain or B-type natriuretic peptide (BNP), and C-type natriuretic peptide (CNP) (Potter et al., 2006, Wu et al., 2009). These peptides are encoded by three separate genes evolved from an ancestral natriuretic peptide gene in primitive vertebrates (Inoue et al., 2003, Takei et al., 2006). The human NPPA gene, encoding the ANP precursor, is on the short arm of chromosome 1 (1p36.21). The gene consists of 3 exons and spans more

ANP biosynthesis and processing

ANP is synthesized as a precursor, i.e. prepro-ANP, a polypeptide of 151 amino acids (Fig. 1). In the endoplasmic reticulum, signal peptidase removes the 25-amino-acid signal peptide, which may be further processed by signal peptide peptidase and released from the cell. Small fragments derived from the ANP signal peptide have been detected in human plasma (Pemberton et al., 2012). After the removal of the signal peptide, the 126-amino-acid pro-ANP is stored in the granules in cardiomyocytes.

Biological functions of ANP

The primary function of ANP is to promote natriuresis and diuresis in the kidney and to relax vascular smooth muscles, thereby regulating blood volume and pressure. This function is mediated by the natriuretic peptide receptor A (NPR-A), also called guanylyl cyclase A, a transmembrane receptor containing an intracellular guanylyl cyclase domain (Koller and Goeddel, 1992, Potter et al., 2006). Upon ANP binding, the receptor is activated, promoting cyclic guanosine monophosphate (cGMP)

NPPA variants in cardiovascular disease

NPPA variants are associated with plasma ANP concentrations, blood pressure levels and cardiovascular diseases (Lynch et al., 2009, Rubattu et al., 2014b). One of the variants, g.–664C>G, is in the 5′ promoter region (Fig. 2). In a European population, the G allele was associated with low plasma ANP levels and high risks of hypertension and cardiac hypertrophy (Rubattu et al., 2006, Rubattu et al., 2007). A similar finding was reported in a Japanese population (Kato et al., 2000).

The variant

ANP as a biomarker

The NPPA gene is up-regulated under physiological and pathological conditions. Mechanical stretch of the atrial wall is one of the most potent stimuli for ANP expression and release (Edwards et al., 1988). The signaling molecules in this process include integrins, p38 MAPK and focal adhesion kinase (Kerkela et al., 2011, Peng et al., 2008). To date, many growth factors and vasoactive molecules have been reported to enhance ANP expression and secretion (Ogawa and de Bold, 2014, Potter et al.,

ANP as a therapeutic agent

Given its unique pleiotropic functions in promoting natriuresis, diuresis and vasodilation and inhibiting aldosterone and renin secretion, ANP represents a promising drug candidate for cardiovascular disease such as HF. In fact, a recombinant form of human ANP, carperitide, has been approved in Japan to treat HF patients (Mitaka et al., 2011, Saito, 2010). The peptide also showed therapeutic benefits in patients with myocardial infarction and kidney disease (Kasama et al., 2007, Kitakaze et

Conclusions

Since the discovery of ANP in the 1980s, we have gained considerable insights into the gene expression, biosynthesis, post-translational processing and biological function of this peptide hormone. In addition to its role in promoting natriuresis, diuresis and vasodilation, ANP also regulates cardiac function, vascular remodeling and energy metabolism. These functions are of significant importance in maintaining cardiovascular and metabolic homeostasis. To date, common NPPA variants have been

Acknowledgments

This review and the corresponding Gene Wiki article are written as part of the Cardiac Gene Wiki Review series—a series resulting from a collaboration between the journal GENE, the Gene Wiki Initiative, and the BD2K initiative. The Cardiac Gene Wiki Initiative is supported by National Institutes of Health (GM089820 and GM114833). Additional support for Gene Wiki Reviews is provided by Elsevier, the publisher of GENE. The authors would like to thank Nancy Fiordalisi for critical reading of this

References (127)

  • M. Gagelmann et al.

    Urodilatin (CDD/ANP-95-126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (alpha-hANP/CDD-99-126)

    FEBS Lett.

    (1988)
  • J.P. Goetze et al.

    Atrial natriuretic peptides in plasma

    Clin. Chim. Acta

    (2015)
  • J.C. Hsieh et al.

    Low serum long-acting natriuretic peptide level correlates with metabolic syndrome in hypertensive patients: a cross-sectional study

    Arch. Med. Res.

    (2013)
  • S. Kasama et al.

    Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction

    J. Am. Coll. Cardiol.

    (2007)
  • N. Kato et al.

    Evaluation of the atrial natriuretic peptide gene in stroke

    Atherosclerosis

    (2002)
  • A.J. Kenny et al.

    Role of endopeptidase-24.11 in the inactivation of atrial natriuretic peptide

    FEBS Lett.

    (1988)
  • M. Kitakaze et al.

    Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials

    Lancet

    (2007)
  • S. Knappe et al.

    Functional analysis of the transmembrane domain and activation cleavage of human corin: design and characterization of a soluble corin

    J. Biol. Chem.

    (2003)
  • M. Lafontan et al.

    Control of lipolysis by natriuretic peptides and cyclic GMP

    Trends Endocrinol. Metab.

    (2008)
  • N. Lara-Castillo et al.

    Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization

    Am. J. Pathol.

    (2009)
  • T. Maack et al.

    Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs

    Am. J. Med.

    (1984)
  • Z. Mandalenakis et al.

    Atrial natriuretic peptide as a predictor of atrial fibrillation in a male population study. The Study of Men Born in 1913 and 1923

    Int. J. Cardiol.

    (2014)
  • P.M. McKie et al.

    A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions

    J. Am. Coll. Cardiol.

    (2009)
  • J.D. Molkentin et al.

    A calcineurin-dependent transcriptional pathway for cardiac hypertrophy

    Cell

    (1998)
  • S. Morikawa et al.

    Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide

    J. Am. Coll. Cardiol.

    (2009)
  • J. Pan et al.

    Genomic structures of the human and murine corin genes and functional GATA elements in their promoters

    J. Biol. Chem.

    (2002)
  • R. Pijnenborg et al.

    The uterine spiral arteries in human pregnancy: facts and controversies

    Placenta

    (2006)
  • S. Rubattu et al.

    Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension

    J. Am. Coll. Cardiol.

    (2006)
  • Y. Saito

    Roles of atrial natriuretic peptide and its therapeutic use

    J. Cardiol.

    (2010)
  • S.D. Anker et al.

    Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies

    Eur. Heart J.

    (2015)
  • P. Arora et al.

    Atrial natriuretic peptide is negatively regulated by microRNA-425

    J. Clin. Invest.

    (2013)
  • M. Bordicchia et al.

    Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes

    J. Clin. Invest.

    (2012)
  • A. Buglioni et al.

    A gut-heart connection in cardiometabolic regulation

    Nat. Med.

    (2013)
  • V. Cannone et al.

    The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population

    Diabetes Care

    (2013)
  • V. Cannone et al.

    Atrial natriuretic peptide genetic variant rs5065 and risk for cardiovascular disease in the general community: a 9-year follow-up study

    Hypertension

    (2013)
  • J.A. Carvajal et al.

    Molecular mechanism of cGMP-mediated smooth muscle relaxation

    J. Cell. Physiol.

    (2000)
  • J.C. Chan et al.

    Hypertension in mice lacking the proatrial natriuretic peptide convertase corin

    Proc. Natl. Acad. Sci. U. S. A.

    (2005)
  • D. Conen et al.

    Natriuretic peptide precursor a gene polymorphisms and risk of blood pressure progression and incident hypertension

    Hypertension

    (2007)
  • D. Conen et al.

    Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women's Genome Health Study

    J. Hypertens.

    (2009)
  • Y. Cui et al.

    Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy

    Nature

    (2012)
  • A.J. de Bold

    Atrial natriuretic factor: a hormone produced by the heart

    Science

    (1985)
  • G.V. Dedoussis et al.

    Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia

    J. Clin. Lab. Anal.

    (2006)
  • D.L. Dries et al.

    Corin gene minor allele defined by 2 missense mutations is common in blacks and associated with high blood pressure and hypertension

    Circulation

    (2005)
  • D. Durocher et al.

    Combinatorial interactions regulating cardiac transcription

    Dev. Genet.

    (1998)
  • B.S. Edwards et al.

    Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor

    Circ. Res.

    (1988)
  • S. Engeli et al.

    Natriuretic peptides enhance the oxidative capacity of human skeletal muscle

    J. Clin. Invest.

    (2012)
  • J.A. Feng et al.

    Pressure-independent enhancement of cardiac hypertrophy in atrial natriuretic peptide-deficient mice

    Clin. Exp. Pharmacol. Physiol.

    (2003)
  • W. Forssmann et al.

    The renal urodilatin system: clinical implications

    Cardiovasc. Res.

    (2001)
  • M.F. Goy et al.

    Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide

    Biochem. J.

    (2001)
  • D.M. Hodgson-Zingman et al.

    Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation

    N. Engl. J. Med.

    (2008)
  • Cited by (135)

    View all citing articles on Scopus
    View full text